Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
AssigneePurdue Research Foundation
InventorsPhilip Stewart Low, Suraj U. Hettiarachchi, Yen-Hsing Li, Jyoti Roy
Life of this patent
Estimating the term…
Abstract
Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
Claims11
A PI-3 kinase inhibitor represented by the formula:
- wherein X is selected from the group consisting of:
A conjugate comprising:
- i) a FAP-binding ligand (TL);
- ii) a linker (L);
- and
- iii) a radical of a PI-3 kinase inhibitor (E) represented by the formula:
- wherein X is selected from the group consisting of:
A compound comprising the formula:
Dependencies are inferred from the claim text.